Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807636 · ClinicalTrials.gov registry record · Phase 3
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,213
- Enrollment target
NCT02807636 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,213 participants.
The verdict
NCT02807636, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,213 participants
- Enrollment target
Study Summary
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Cisplatin
- OTHER Placebo
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,213 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2024-02-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02807636
The ClinicalTrials.gov registry entry for NCT02807636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02807636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02807636 about?
NCT02807636 is a clinical study titled "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma". A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
What is the current status of trial NCT02807636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,213 participants. The study started on 2016-06-30. Estimated completion is 2024-02-12.
What interventions are being tested in trial NCT02807636?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Placebo (OTHER), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02807636?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.